Filter Results:
(298)
Show Results For
- All HBS Web
(298)
- People (1)
- News (83)
- Research (187)
- Multimedia (4)
- Faculty Publications (124)
Show Results For
- All HBS Web
(298)
- People (1)
- News (83)
- Research (187)
- Multimedia (4)
- Faculty Publications (124)
- October 2008
- Case
Diagnostic Genomics
By: Regina E. Herzlinger and Mark P. Allyn
Should this gene detection firm enter the business of providing tests for the detection of genetic diseases? If so, how should it prioritize the tests it could develop? View Details
Keywords: Health Testing and Trials; Market Entry and Exit; Product Development; Genetics; Strategy; Health Industry; Medical Devices and Supplies Industry
Herzlinger, Regina E., and Mark P. Allyn. "Diagnostic Genomics." Harvard Business School Case 309-040, October 2008.
- 24 Feb 2015
- News
Culture Clash: Silicon Valley vs. the U.S. Government
- April 2001 (Revised January 2003)
- Case
Robert Shapiro and Monsanto
Traces Monsanto's efforts to become a global biotech powerhouse under Shapiro's leadership. Examines how his crusade to save the world through genetic modification foundered. View Details
Keywords: Genetics; Supply Chain Management; Alliances; Global Strategy; Cross-Cultural and Cross-Border Issues; Biotechnology Industry
Watkins, Michael D., and Ann Leamon. "Robert Shapiro and Monsanto." Harvard Business School Case 801-426, April 2001. (Revised January 2003.)
- October 2001
- Case
TIGR and ILRI: Solving Problems with Genomics
By: Ray A. Goldberg and James M Beagle
Discusses nonprofit institutional leadership applying advances in genetic science to solve health and animal problems in industrial countries and the developing world. View Details
- 26 Jan 2022
- News
To Succeed With Purpose, Make it Personal
- February 2006 (Revised August 2006)
- Case
deCODE Genetics: Hunting for Genes to Develop Drugs
By: Debora L. Spar
In 1996, Kari Stefansson launched a new kind of biotechnology company and a whole new way of attacking diseases. Based in Iceland, his firm, deCODE Genetics, plans to identify the individual genetic markers that lead to society's most prevalent diseases. To do so, it... View Details
Keywords: Information; Innovation Strategy; Genetics; Ethics; Health Disorders; Biotechnology Industry; Iceland
Spar, Debora L., and Chris Bebenek. "deCODE Genetics: Hunting for Genes to Develop Drugs." Harvard Business School Case 706-040, February 2006. (Revised August 2006.)
- 13 Apr 2017
- News
What Precision Medicine Can Learn from the NFL
- October 2003 (Revised February 2004)
- Case
Launching the European Food Safety Authority
By: Ray A. Goldberg and Hal Hogan
The first food safety commission is established for the European Union. How does it handle food safety, scientific evaluations, and people's attitudes toward scientific changes in food growing and processing--for example, genetically modified organisms? View Details
Goldberg, Ray A., and Hal Hogan. "Launching the European Food Safety Authority." Harvard Business School Case 904-414, October 2003. (Revised February 2004.)
- 09 Apr 2012
- News
Who Sways the USDA on GMO Approvals?
- 09 Apr 2012
- Research & Ideas
Who Sways the USDA on GMO Approvals?
asking that question through research on the controversial issue of genetically modified organisms (GMOs), agricultural products that are genetically altered to increase yield, incorporate pesticide... View Details
- 26 Jan 2024
- Blog Post
HBS Alumna Fighting Cancer with a Novel Cell Therapy
Ananya Zutshi (MS/MBA 2021) wanted a career in pharmacology biotech, but wasn’t sure if she wanted to be on the management side or scientific side. She studied biomedical engineering as an undergraduate at Duke University, where she participated in View Details
- January 2014 (Revised December 2014)
- Case
GenapSys: Business Models for the Genome
By: Richard G. Hamermesh, Joseph B. Fuller and Matthew Preble
GenapSys, a California-based startup, was soon to release a new DNA sequencer that the company's founder, Hesaam Esfandyarpour, believed was truly revolutionary. The sequencer would be substantially less expensive—potentially costing just a few thousand dollars—and... View Details
Keywords: DNA Sequencing; Life Sciences; Business Model; Innovation ＆ Entrepreneurship; Health Care and Treatment; Genetics; Business Strategy; Biotechnology Industry; Pharmaceutical Industry; Technology Industry; Health Industry; Medical Devices and Supplies Industry; United States
Hamermesh, Richard G., Joseph B. Fuller, and Matthew Preble. "GenapSys: Business Models for the Genome." Harvard Business School Case 814-050, January 2014. (Revised December 2014.)
- 12 Feb 2025
- Video
Who owns it? The Ownership Project on how property rights shape business
- April 2019
- Teaching Note
The a2 Milk Company
By: Benjamin C. Esty and Daniel Fisher
The a2 Milk Company (a2MC) became the most valuable company listed on the New Zealand stock exchange in 2018 by capitalizing on a biochemical discovery related to the protein composition of cow's milk. Because many people find the A1 protein difficult to digest, and... View Details
Keywords: Judo Economics; Market Entry; Innovation; Barriers To Response; Industry Attractiveness; Advantage Horizon; Sustainability; First-mover Advantage; Scope; Strategy Execution; Strategic Evolution; Biochemistry; Genetics; Branding; Commodity; Milk; Dairy; Infant Formula; Farming; Porter's Five Forces; Market Entry and Exit; Disruption; Innovation and Invention; Competitive Advantage; Corporate Strategy; Value Creation; Competition; Brands and Branding; Five Forces Framework; Consumer Products Industry; New Zealand; Australia; China
- 28 Feb 2019
- News
Pursuing Precision Medicine at Intermountain Healthcare
- January 2019 (Revised February 2019)
- Supplement
The a2 Milk Company
By: Benjamin C. Esty, Daniel Fisher and Greg Saldutte
The a2 Milk Company (a2MC) became the most valuable company listed on the New Zealand stock exchange in 2018 by capitalizing on a biochemical discovery related to the protein composition of cow's milk. Because many people find the A1 protein difficult to digest, and... View Details
Keywords: Judo Economics; Market Entry; Innovation; Barriers To Response; Industry Attractiveness; Advantage Horizon; Sustainability; First-mover Advantage; Scope; Strategy Execution; Strategic Evolution; Biochemistry; Genetics; Branding; Commodity; Milk; Dairy; Infant Formula; Farming; Porter's Five Forces; Competitive Advantage; Corporate Strategy; Value Creation; Competition; Market Entry and Exit; Disruption; Innovation and Invention; Five Forces Framework; Consumer Products Industry; New Zealand; Australia; China
- October 2001 (Revised April 2002)
- Case
Calgene, Inc.
By: Ray A. Goldberg and John T. Gourville
In 1993, Calgene is on the verge of introducing the world's first genetically engineered plant product--a tomato will taste better and stay fresh longer. At the same time, it is using biotechnology to produce improved plant products for the cottonseed and the... View Details
Keywords: Information Technology; Marketing Strategy; Market Entry and Exit; Product Launch; Innovation Strategy; Social Issues; Production; Problems and Challenges; Biotechnology Industry; Agriculture and Agribusiness Industry
Goldberg, Ray A., and John T. Gourville. "Calgene, Inc." Harvard Business School Case 502-041, October 2001. (Revised April 2002.)
- December 2002 (Revised April 2007)
- Case
Cargill (A)
By: Ray A. Goldberg and Jose M. M. Porraz
Cargill is one of the world's leading marketers, processors, and distributors of agricultural, food, industrial, and financial products. In 1998, the company decided to develop a strategic intent to restructure and refocus the company. It did so in response to the... View Details
Keywords: Business Strategy; Agribusiness; Restructuring; Industry Structures; Global Strategy; Genetics; Demand and Consumers; Agriculture and Agribusiness Industry
Goldberg, Ray A., and Jose M. M. Porraz. "Cargill (A)." Harvard Business School Case 903-420, December 2002. (Revised April 2007.)
- December 2005 (Revised August 2006)
- Case
Amgen Inc.'s Epogen--Commercializing the First Biotech Blockbuster Drug
By: Felix Oberholzer-Gee and Dennis A. Yao
Amgen Inc.'s Epogen was the first biotech blockbuster drug. Epogen helped prevent anemia, a condition that leads to severe fatigue, increased risk of cardiovascular disease, and even death. At the time, the market for Epogen, which included dialysis patients and... View Details
Keywords: Health Care and Treatment; Strategic Planning; Competition; Patents; Innovation and Invention; Pharmaceutical Industry; Biotechnology Industry; United States
Oberholzer-Gee, Felix, and Dennis A. Yao. "Amgen Inc.'s Epogen--Commercializing the First Biotech Blockbuster Drug." Harvard Business School Case 706-454, December 2005. (Revised August 2006.)